(Date:12/14/2009)... Pa., Dec. 14 MODA Technology Partners, ... (EM), utility and product testing for the Pharmaceutical ... 3.0, the company,s third generation mobile data acquisition ... organizations to further automate their regulated manufacturing processes. ... capabilities: ,, Fully-Configurable Test Methods: ...
(Date:12/13/2009)... have identified plant enzymes that may help to engineer ... use water more efficiently. The finding could help to ... , Plants take in the carbon dioxide they need ... of leaves. But for each molecule of the gas ... same openings. The pores can tighten to save water ...
(Date:12/13/2009)... New Haven, Conn.A team led by Yale University ... in whole blood for the first time. Their ... online publication of Nature Nanotechnology , could ... of cancer and other diseases. , ... Professor of Engineering & Applied Science, and Tarek ...
Breaking Biology News(10 mins):MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Physicians Interactive Acquires Skyscape Inc Becoming Worlds Leading Mobile Medical Information Provider 52526 1Physicians Interactive Acquires Skyscape Inc Becoming Worlds Leading Mobile Medical Information Provider 52526 2Physicians Interactive Acquires Skyscape Inc Becoming Worlds Leading Mobile Medical Information Provider 52526 3Physicians Interactive Acquires Skyscape Inc Becoming Worlds Leading Mobile Medical Information Provider 52526 4Beta Blockers Tied to Higher Cataract Risk 52521 1Beta Blockers Tied to Higher Cataract Risk 52521 2Beta Blockers Tied to Higher Cataract Risk 52521 3Medifast Inc to Announce Second Quarter Fiscal Year 2009 Financial Results on Thursday July 30 2009 52517 1Medifast Inc to Announce Second Quarter Fiscal Year 2009 Financial Results on Thursday July 30 2009 52517 2(Date:12/14/2009)... 14 Boston Scientific Corporation (NYSE: ... offering of $2 billion aggregate principal amount of its ... The public offering consists of $850 million of 4.50 ... percent notes due January 2020 and $300 million of ... plans to use the net proceeds for general corporate ...
(Date:12/14/2009)... of Brookfield Engineering’s Powder Flow Tester – helping Brookfield move ... footprint and more compact design. , ... ... US-based thermoforming company, has completed the delivery of Brookfield Engineering’s ... to a plastic enclosure with a smaller footprint and more ...
(Date:12/11/2009)... Colo., December 10, 2009 miRagen Therapeutics, Inc., ... by developing innovative microRNA-based therapeutics for cardiovascular and ... demonstrating that microRNA-206 (miR-206) plays a crucial role ... or Lou Gehrig,s disease) and in neuromuscular synaptic ... the December 11 issue of the journal ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4... Inc. (OTC Bulletin Board: CSBR), a company engaged ... specific data to,enhance the value of oncology drugs, ... Under the terms of the private investment,Champions Biotechnology ... at $1.75 per share. There were no fees ...
... Company Taking ... Actions to Address New Challenges, KENILWORTH, N.J., April 23 ... for the first,quarter of 2008, reviewed progress on its ongoing ... addressed recent,events affecting the Merck/Schering-Plough cholesterol franchise., "The first ...
... Dutch researchers in Amsterdam have collaborated using for the ... Depression research. They used postmortem human brain tissue that ... purposes and investigated a region in the basal part ... be of crucial importance for the development of symptoms ...
Other Biology Technology:Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share 2Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share 3Schering-Plough Reports Financial Results for First Quarter of 2008 2Schering-Plough Reports Financial Results for First Quarter of 2008 3Schering-Plough Reports Financial Results for First Quarter of 2008 4Schering-Plough Reports Financial Results for First Quarter of 2008 5Schering-Plough Reports Financial Results for First Quarter of 2008 6Schering-Plough Reports Financial Results for First Quarter of 2008 7Schering-Plough Reports Financial Results for First Quarter of 2008 8Schering-Plough Reports Financial Results for First Quarter of 2008 9Schering-Plough Reports Financial Results for First Quarter of 2008 10Schering-Plough Reports Financial Results for First Quarter of 2008 11Schering-Plough Reports Financial Results for First Quarter of 2008 12Schering-Plough Reports Financial Results for First Quarter of 2008 13Schering-Plough Reports Financial Results for First Quarter of 2008 14Schering-Plough Reports Financial Results for First Quarter of 2008 15Schering-Plough Reports Financial Results for First Quarter of 2008 16Schering-Plough Reports Financial Results for First Quarter of 2008 17Schering-Plough Reports Financial Results for First Quarter of 2008 18Schering-Plough Reports Financial Results for First Quarter of 2008 19Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... forces with the Mickle Laboratory Engineering Company ... This tissue sectioning system has been designed ... experiments and to be especially applicable to ... or from small organs. Its special features ...
Without sodium bicarbonate. Sterile, Cell culture tested...
... The Bioactive peptides are molecules of peptidic ... behaviour or activity which can be developed ... chemical and agro-food applications. In this way ... with superior properties for therapeutic applications. Primm ...
Biology Products:Biology NavigationMedical Navigation